Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FTY720: early clinical experience.

D Dragun1, L Fritsche, T Boehler

  • 1University Hospital Charité, Department of Nephrology, Campus Mitte, Berlin, Germany.

Transplantation Proceedings
|March 26, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reactivity of the rat distal colon to autoantibodies targeting angiotensin type I receptors: <b>PS219</b>.

Porto biomedical journal·2020
Same author

The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: Improving Antibody-Mediated Rejection Diagnostics: Strengths, Unmet Needs, and Future Directions.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Anti-ETAR and anti-AT1R autoantibodies are elevated in patients with endstage cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2014
Same author

Serum levels for midkine, a heparin-binding growth factor, inversely correlate with angiotensin and endothelin receptor autoantibody titers in patients with macroangiopathy.

International angiology : a journal of the International Union of Angiology·2014
Same author

Acute cellular rejection with isolated v-lesions is not associated with more favorable outcomes than vascular rejection with more tubulointerstitial inflammations.

Clinical transplantation·2014
Same journal

Acute Rejection Mediated by Preformed Anti-HLA-C Antibody in a Kidney Transplant Patient: A Case Report.

Transplantation proceedings·2026
Same journal

Liver Transplantation for Metastatic Neuroendocrine Tumors: A Single-Center Experience in a Brazilian Referral Center.

Transplantation proceedings·2026
Same journal

Analysis of the Cost of Maintaining Effective Donors and Nondonors of Organs and Tissues in Intensive Care Units.

Transplantation proceedings·2026
Same journal

Adolescence and Pediatric Heart Transplantation: Impact of Non-Adherence on Mortality: A Single-Center Experience.

Transplantation proceedings·2026
Same journal

Impact of Family-Based Care on the Outcome of Brain Death and Humanization in the Process of Multiple Organ Donation: Case Report.

Transplantation proceedings·2026
Same journal

Karnofsky Performance Status Is Associated with Patient and Graft Survival After Liver Retransplantation.

Transplantation proceedings·2026
See all related articles

FTY720, a novel sphingosine 1-phosphate receptor (S1P-R) agonist, shows promise in transplantation by prolonging allograft survival and demonstrating synergistic effects with other immunosuppressants. It offers a well-tolerated, lymphocyte-specific immunomodulatory profile for transplant patients.

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Pharmacology

Background:

  • FTY720 represents a new class of immunomodulators, acting as sphingosine 1-phosphate receptor (S1P-R) agonists.
  • It has demonstrated significant efficacy in preclinical transplantation models, prolonging allograft survival.
  • Synergistic effects with calcineurin and proliferation inhibitors suggest potential for combination therapy in transplant patients.

Purpose of the Study:

  • To evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic profile of FTY720 in renal transplant patients.
  • To assess the potential of FTY720 as an adjunct to standard immunosuppressive regimens.
  • To investigate the combination therapy of FTY720 with cyclosporine (CsA) in transplant pharmacotherapy.

Main Methods:

Related Experiment Videos

  • Phase I clinical studies were conducted in stable renal transplant patients on a cyclosporine (CsA)-based regimen.
  • Pharmacokinetic analysis assessed dose-proportional exposure, interpatient variability, and elimination half-life.
  • Pharmacodynamic assessment focused on changes in peripheral blood cell counts, particularly lymphocytes, monocytes, and granulocytes.

    • Main Results:

    • FTY720 exhibited a tolerable safety profile in Phase I studies when combined with CsA.
    • Pharmacokinetics revealed linear dose-proportional exposure, moderate variability, and a long elimination half-life (89-157 hours), supporting once-daily dosing without monitoring.
    • Pharmacodynamics showed a significant, lymphocyte-specific reduction (up to 85%) in peripheral blood counts, with no impact on monocytes or granulocytes.

    Conclusions:

    • FTY720 is a well-tolerated immunomodulator in renal transplant patients, particularly when used with CsA.
    • Its unique lymphocyte-specific mechanism and favorable pharmacokinetic profile make it a promising agent for preventing graft rejection.
    • FTY720 offers potential for developing more effective and less toxic immunosuppressive strategies in transplantation.